Dexycu may receive extension of pass-through payment status

dexycu may receive extension of pass through payment status

Sumary of Dexycu may receive extension of pass-through payment status:

  • Back to Healio EyePoint Pharmaceuticals anticipates a 9-month extension to Dexycu’s pass-through payment status, according to a press release.
  • The current pass-through payment status for Dexycu (dexamethasone intraocular suspension 9%) would expire on March 31, 2022, without an extension, the release said.
  • CMS released the 2022 draft Hospital Outpatient Prospective Payment System rule on July 19, with a final rule expected to come in November, the release said.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close